{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T10:04:48Z","timestamp":1772791488650,"version":"3.50.1"},"reference-count":77,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2004,11,1]],"date-time":"2004-11-01T00:00:00Z","timestamp":1099267200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2004,11,1]],"date-time":"2004-11-01T00:00:00Z","timestamp":1099267200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Steroid Biochemistry and Molecular Biology"],"published-print":{"date-parts":[[2004,11]]},"DOI":"10.1016\/j.jsbmb.2004.10.005","type":"journal-article","created":{"date-parts":[[2005,1,4]],"date-time":"2005-01-04T07:16:53Z","timestamp":1104823013000},"page":"287-295","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":72,"title":["Endocrine treatment of prostate cancer"],"prefix":"10.1016","volume":"92","author":[{"given":"Teuvo","family":"Tammela","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jsbmb.2004.10.005_bib1","first-page":"293","article-title":"Studies on prostate cancer: I. The effect of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate","volume":"1","author":"Huggins","year":"1941","journal-title":"Cancer Res."},{"key":"10.1016\/j.jsbmb.2004.10.005_bib2","doi-asserted-by":"crossref","first-page":"3009","DOI":"10.1002\/1097-0142(20000615)88:12+<3009::AID-CNCR17>3.0.CO;2-E","article-title":"Hormone therapy for patients with prostate carcinoma","volume":"88","author":"Klotz","year":"2000","journal-title":"Cancer"},{"key":"10.1016\/j.jsbmb.2004.10.005_bib3","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1002\/pros.2990110106","article-title":"Quantal relationship between prosttaic dihydrotestosterone and prostatic cell content: critical threshold concept","volume":"11","author":"Kyprianou","year":"1987","journal-title":"Prostate"},{"key":"10.1016\/j.jsbmb.2004.10.005_bib4","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1159\/000067996","article-title":"PSA decline is an independent prognostic marker in hormonally treated prostate cancer","volume":"36","author":"Palmberg","year":"1999","journal-title":"Eur. Urol."},{"issue":"Suppl. 2A","key":"10.1016\/j.jsbmb.2004.10.005_bib5","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/S0090-4295(02)02395-6","article-title":"National comprehensive cancer network guidelines for the management of prostate cancer","volume":"61","author":"Scherr","year":"2003","journal-title":"Urology"},{"key":"10.1016\/j.jsbmb.2004.10.005_bib6","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1146\/annurev.med.45.1.391","article-title":"Gonadotropin-releasing hormone and its analogs","volume":"45","author":"Conn","year":"1994","journal-title":"Annu. Rev. Med."},{"key":"10.1016\/j.jsbmb.2004.10.005_bib7","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1046\/j.1464-410X.2003.03054.x","article-title":"The clinical implications of the difference between castration, gonadotropin releasing-hormone (GnRH) antagonists and agonist treatment on the morphology and expression of GnRH receptors in the rat ventral prostate","volume":"91","author":"Tieva","year":"2003","journal-title":"BJU Int."},{"key":"10.1016\/j.jsbmb.2004.10.005_bib8","doi-asserted-by":"crossref","first-page":"566","DOI":"10.7326\/0003-4819-132-7-200004040-00009","article-title":"Single-therapy androgen suppression in men with advanced prostate cancer: a systematic review and meta-analysis","volume":"132","author":"Seidenfeld","year":"2000","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.jsbmb.2004.10.005_bib9","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/S0090-4295(01)01235-3","article-title":"Is the flare phenomenon clinically significant?","volume":"58","author":"Bubley","year":"2001","journal-title":"Urology"},{"key":"10.1016\/j.jsbmb.2004.10.005_bib10","doi-asserted-by":"crossref","first-page":"C113","DOI":"10.1016\/0303-7207(91)90116-A","article-title":"Intracrinology","volume":"78","author":"Labrie","year":"1991","journal-title":"Mol. Cell. Endocrinol."},{"key":"10.1016\/j.jsbmb.2004.10.005_bib11","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1002\/(SICI)1097-0142(19971101)80:9<1835::AID-CNCR23>3.0.CO;2-5","article-title":"The results of prostate carcinoma screening in the U.S. as reflected in the surveillance, epidemiologu\u00fd, and end results program","volume":"80","author":"Smart","year":"1997","journal-title":"Cancer"},{"key":"10.1016\/j.jsbmb.2004.10.005_bib12","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1016\/S0140-6736(00)02163-2","article-title":"Maximum androgen blockade in advanced prostate cancer: an overview of the randomised trials","volume":"355","year":"2000","journal-title":"Lancet"},{"key":"10.1016\/j.jsbmb.2004.10.005_bib13","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1002\/cncr.10647","article-title":"Systematic review and meta-analysis of monotherapy compared with combined androgen blockade for patients with advanced prostate carcinoma","volume":"95","author":"Samson","year":"2002","journal-title":"Cancer"},{"key":"10.1016\/j.jsbmb.2004.10.005_bib14","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1056\/NEJM199810083391504","article-title":"Bilateral orchiectomy with or without flutamide for metastatic prostate cancer","volume":"339","author":"Eisenberger","year":"1998","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jsbmb.2004.10.005_bib15","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.1073\/pnas.98.4.1829","article-title":"Luteinizing hormone-releasing hormone (LH-RH) antagonist Cetrorelix down-regulates the mRNA expression of pituitary receptors for LH-RH by counteracting the stimulatory effect of endogenous LH-RH","volume":"98","author":"Kovacs","year":"2001","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.jsbmb.2004.10.005_bib16","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1016\/S0022-5347(05)67947-5","article-title":"High incidence of receptors for luteinizing hormone-releasing (LHRH) and LHRH receptor gene expression in human prostate cancers","volume":"163","author":"Halmos","year":"2000","journal-title":"J. Urol."},{"key":"10.1016\/j.jsbmb.2004.10.005_bib17","first-page":"1011","article-title":"Treatment and survival of patients with cancer of the prostate","volume":"124","year":"1967","journal-title":"Surg. Gynecol. Obstet."},{"key":"10.1016\/j.jsbmb.2004.10.005_bib18","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1111\/j.1464-410X.1990.tb14728.x","article-title":"Effect of parenteral oestrogen on the regulation system in patients with prostatic carcinoma","volume":"65","author":"Herinkson","year":"1990","journal-title":"Br. J. Urol."},{"key":"10.1016\/j.jsbmb.2004.10.005_bib19","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1046\/j.1464-410x.1998.00688.x","article-title":"Parenteral polyestradiol phosphate vs orchidectomy in the treatment of advanced prostatic cancer, Efficacy and cardiovascular complications: a 2-year follow-up report of a national, prospective prostatic cancer study","volume":"82","author":"Mikkola","year":"1998","journal-title":"Br. J. Urol."},{"key":"10.1016\/j.jsbmb.2004.10.005_bib20","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1080\/003655902762467549","article-title":"Parenteral estrogen versus combined androgen deprivation in the treatment of metastatic prostate cancer","volume":"36","author":"Hedlund","year":"2002","journal-title":"Scand. J. Urol. Nephrol."},{"key":"10.1016\/j.jsbmb.2004.10.005_bib21","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1002\/1097-0045(2000)45:10+<32::AID-PROS7>3.0.CO;2-V","article-title":"Side effects of endocrine treatment and their mechanisms: castration, antiandrogens and estrogens","volume":"10","author":"Hedlund","year":"2000","journal-title":"Prostate Suppl."},{"key":"10.1016\/j.jsbmb.2004.10.005_bib22","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1016\/S0022-5347(17)32530-2","article-title":"Prevalence and duration of hot flushes after surgical and medical castration in men with prostatic carcinoma","volume":"152","author":"Karling p","year":"1994","journal-title":"J. Urol."},{"key":"10.1016\/j.jsbmb.2004.10.005_bib23","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/S0022-5347(05)65973-3","article-title":"Prospective evaluation of hot flushes during treatment with parenteral estrogen or complete androgen ablation for metastatic carcinoma of the prostate","volume":"166","author":"Spetz","year":"2001","journal-title":"J. Urol."},{"key":"10.1016\/j.jsbmb.2004.10.005_bib24","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1046\/j.1464-410X.1997.00234.x","article-title":"Anaemia associated with androgen deprivation in patients with prostatic cancer receiving combined hormone blockade","volume":"79","author":"Strum","year":"1997","journal-title":"Br. J. Urol."},{"key":"10.1016\/j.jsbmb.2004.10.005_bib25","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1159\/000473597","article-title":"Preferential preservation of bone mineral mineralization by LHRH agonists in the treatment of metastatic prostate cancer","volume":"19","author":"Clarke","year":"1991","journal-title":"Eur. Urol."},{"key":"10.1016\/j.jsbmb.2004.10.005_bib26","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/S0022-5347(01)65165-6","article-title":"Osteoporosis after orchiectomy for prostate cancer","volume":"157","author":"Daniell","year":"1997","journal-title":"J. Urol."},{"key":"10.1016\/j.jsbmb.2004.10.005_bib27","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1016\/S0302-2838(03)00379-8","article-title":"Osteoporosis during continuous androgen deprivation: influence of the modality and length of treatment","volume":"44","author":"Morote","year":"2003","journal-title":"Eur. Urol."},{"key":"10.1016\/j.jsbmb.2004.10.005_bib28","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1002\/(SICI)1097-0142(19970201)79:3<545::AID-CNCR17>3.0.CO;2-3","article-title":"Bone fractures associated with luteinizing hormone-releasing hormone agonist used in the treatment of prostate cancer","volume":"79","author":"Townsend","year":"1997","journal-title":"Cancer"},{"issue":"Suppl. 3A","key":"10.1016\/j.jsbmb.2004.10.005_bib29","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/S0090-4295(02)01579-0","article-title":"Osteoporosis during androgen deprivation therapy for prostate cancer","volume":"60","author":"Smith","year":"2002","journal-title":"Urology"},{"issue":"Suppl. 2A","key":"10.1016\/j.jsbmb.2004.10.005_bib30","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/S0090-4295(01)01251-1","article-title":"Osteoporosis due to androgen deprivation in men with prostate cancer","volume":"58","author":"Daniell","year":"2001","journal-title":"Urology"},{"key":"10.1016\/j.jsbmb.2004.10.005_bib31","first-page":"314a","article-title":"Prospective serial measurements of bone mineral density in prostate cancer patients without bone metastases treated with intermittent androgen suppression","volume":"18","author":"Higano","year":"1999","journal-title":"Proc. Am. Soc. Clin. Oncol. Suppl."},{"key":"10.1016\/j.jsbmb.2004.10.005_bib32","doi-asserted-by":"crossref","first-page":"31","DOI":"10.3109\/00365598209179637","article-title":"The effects of orchidectomy, estrogens, and cyproterone acetate on plasma testosterone, LH, and FSH concentrations in patients with carcinoma of the prostate","volume":"16","author":"Varenhorst","year":"1982","journal-title":"Scand. J. Urol. Nephrol."},{"key":"10.1016\/j.jsbmb.2004.10.005_bib33","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1002\/pros.2990210514","article-title":"The position of cyproterone acetate (CPA), a steroidal anti-androgen, in the treatment of prostate cancer","volume":"4","author":"de Voogt","year":"1992","journal-title":"Prostate Suppl."},{"key":"10.1016\/j.jsbmb.2004.10.005_bib34","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1016\/0002-9343(92)90741-S","article-title":"Incidence of liver toxicity associated with the use of flutamide in prostatic cancer patients","volume":"92","author":"Gomez","year":"1992","journal-title":"Am. J. Med."},{"key":"10.1016\/j.jsbmb.2004.10.005_bib35","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1159\/000019548","article-title":"Are non-steroidal anti-androgens appropriate as monotherapy in advanced prostate cancer?","volume":"33","author":"Boccon-Gibod","year":"1998","journal-title":"Eur. Urol."},{"key":"10.1016\/j.jsbmb.2004.10.005_bib36","first-page":"268","article-title":"Non-steroidal antiandrogen monotherapy of advanced prostate cancer \u2013 a reasonable option?","volume":"7","author":"Boccon-Gibod","year":"1997","journal-title":"Curr. Opin. Urol."},{"key":"10.1016\/j.jsbmb.2004.10.005_bib37","doi-asserted-by":"crossref","first-page":"2027","DOI":"10.1200\/JCO.1999.17.7.2027","article-title":"Bicalutamide monotherapy versus flutamide plus goserelin in prostate cancer patients: results of Italian Prostate Cancer Project study","volume":"17","author":"Boccardo","year":"1999","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.jsbmb.2004.10.005_bib38","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1016\/S0022-5347(05)67032-2","article-title":"Bicalutamide monotherapy compared with castration in patients with nonmetastatic locally advanced prostate cancer: 6.3 years followup","volume":"164","author":"Iversen","year":"2000","journal-title":"J. Urol."},{"key":"10.1016\/j.jsbmb.2004.10.005_bib39","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/S0022-5347(05)64652-6","article-title":"Bicalutamide as immediate therapy either alone or as adjuvant to standard care of patients with localized or locally advanced prostate cancer: first analysis of the early prostate cancer program","volume":"168","author":"See","year":"2002","journal-title":"J. Urol."},{"key":"10.1016\/j.jsbmb.2004.10.005_bib40","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1111\/j.1365-2265.1994.tb02585.x","article-title":"Endocrine profiles during administration of the new non-steroidal anti-androgen Casodex in prostate cancer","volume":"41","author":"Verhelst","year":"1994","journal-title":"Clin. Endocrinol. (Oxf)"},{"key":"10.1016\/j.jsbmb.2004.10.005_bib41","first-page":"447","article-title":"Blackledge G. TI: A randomised comparison of \u201cCasodex\u201d (bicalutamide) 150 mg monotherapy versus castration in the treatment of metastatic and locally advanced prostate cancer","volume":"33","author":"Tyrrell","year":"1998","journal-title":"SO: Eur. Urol."},{"key":"10.1016\/j.jsbmb.2004.10.005_bib42","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/S0302-2838(02)00311-1","article-title":"A randomised comparison of bicalutamide (\u201cCasodex\u201d, 150 mg versus placebo as immediate therapy as alone or as adjuvant to standard care for early non-metastatic prostate cancer. First report from the Scandinavian Prostatic Cancer Group Study N. 6","volume":"42","author":"Iversen","year":"2002","journal-title":"Eur. Urol."},{"key":"10.1016\/j.jsbmb.2004.10.005_bib43","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1038\/sj.pcan.4500314","article-title":"Gynaecomastia: aetiology and treatment options","volume":"2","author":"Tyrrell","year":"1999","journal-title":"Prostate Cancer Prostatic Dis."},{"key":"10.1016\/j.jsbmb.2004.10.005_bib44","first-page":"2275","article-title":"Effetcts of adrogen withdrawal on the stem cell composition of the Shionogi carcinoma","volume":"50","author":"Bruchovsky","year":"1990","journal-title":"Cancer Res."},{"key":"10.1016\/j.jsbmb.2004.10.005_bib45","first-page":"187","article-title":"Management of locally advanced prostate cancer: a European consensus","volume":"57","author":"Boccon-Gibod","year":"2003","journal-title":"IJCP"},{"key":"10.1016\/j.jsbmb.2004.10.005_bib46","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/S0302-2838(03)00375-0","article-title":"Intermittent maximal androgen blockade in patients with metastatic prostatic cancer: an EORTC feasibility study","volume":"44","author":"Albrecht","year":"2003","journal-title":"Eur. Urol."},{"key":"10.1016\/j.jsbmb.2004.10.005_bib47","doi-asserted-by":"crossref","first-page":"115","DOI":"10.2165\/00002512-200320020-00003","article-title":"Value of endocrine therapy for early and locally advanced prostate cancer","volume":"20","author":"Wirth","year":"2003","journal-title":"Drugs Aging"},{"key":"10.1016\/j.jsbmb.2004.10.005_bib48","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/S0022-5347(05)65393-1","article-title":"Puras-Baez, Neoadjuvant androgen ablation before radical prostatectomy in cT2bNxMo prostate cancer: 5-year results","volume":"167","author":"Soloway","year":"2002","journal-title":"J. Urol."},{"key":"10.1016\/j.jsbmb.2004.10.005_bib49","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/S0090-4295(00)00627-0","article-title":"Long-term neoadjuvant therapy prior to radical prostatectomy: evaluation of risk for biochemical recurrence at 5-year follow-up","volume":"56","author":"Gleave","year":"2000","journal-title":"Urology"},{"key":"10.1016\/j.jsbmb.2004.10.005_bib50","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1159\/000020047","article-title":"Adjuvant and neoadjuvant hormonal therapy for prostate cancer","volume":"36","author":"Tyrrell","year":"1999","journal-title":"Eur. Urol."},{"key":"10.1016\/j.jsbmb.2004.10.005_bib51","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1016\/S0022-5347(05)67008-5","article-title":"Neoadjuvant hormonal ablative therapy before radical. Radical Prostatectomy: a review. Is it indicated?","volume":"164","author":"Scolieri","year":"2000","journal-title":"J. Urol."},{"key":"10.1016\/j.jsbmb.2004.10.005_bib52","doi-asserted-by":"crossref","first-page":"2208","DOI":"10.1016\/S0022-5347(05)65536-X","article-title":"Role of early adjuvant hormonal therapy after radical prostatectomy for prostate cancer","volume":"166","author":"Zincke","year":"2001","journal-title":"J. Urol."},{"key":"10.1016\/j.jsbmb.2004.10.005_bib53","doi-asserted-by":"crossref","first-page":"1821","DOI":"10.1016\/S0022-5347(17)32394-7","article-title":"The incidence and significance of detectable levels of serum prostate specific antigen after radical prostatectomy","volume":"152","author":"Trapasso","year":"1994","journal-title":"J. Urol."},{"key":"10.1016\/j.jsbmb.2004.10.005_bib54","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1056\/NEJM199912093412401","article-title":"Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer","volume":"341","author":"Messing","year":"1999","journal-title":"N. Eng. J. Med."},{"key":"10.1016\/j.jsbmb.2004.10.005_bib55","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/S0094-0143(05)70386-4","article-title":"Prostate-specific antigen after anatomic radical retropubic prostatectomy: patterns of recurrence and cancer control","volume":"24","author":"Pound","year":"1997","journal-title":"Urol. Clin. North. Am."},{"key":"10.1016\/j.jsbmb.2004.10.005_bib56","first-page":"48","article-title":"Neoadjuvant therapy prior to radiotherapy for clinically localized prostate cancer","volume":"32","author":"Roach","year":"1997","journal-title":"Eur. Urol."},{"key":"10.1016\/j.jsbmb.2004.10.005_bib57","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/S0360-3016(96)00325-2","article-title":"Quantifying regional hypoxia in human tumors with positron emission tomography of (18F) fluoromisonidazole: a pretherapy study of 37 patients","volume":"36","author":"Rasey","year":"1996","journal-title":"Int. J. Radiot. Oncol. Biol. Phys."},{"key":"10.1016\/j.jsbmb.2004.10.005_bib58","first-page":"2493","article-title":"Quiescence in R3327-G rat prostate tumors after androgen ablation","volume":"15","author":"Pollack","year":"1997","journal-title":"Cancer Res."},{"key":"10.1016\/j.jsbmb.2004.10.005_bib59","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/S0090-4295(02)01566-2","article-title":"Radiation and hormonal therapy for locally advanced and clinically localized prostate cancer","volume":"60","author":"D\u2019Amico","year":"2002","journal-title":"Urology"},{"issue":"Suppl. 3A","key":"10.1016\/j.jsbmb.2004.10.005_bib60","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/S0090-4295(97)00168-4","article-title":"Neoadjuvant androgen ablation prior to radiotherapy for prostate cancer: reducing the potential morbidity of therapy","volume":"49","author":"Zelefsky","year":"1997","journal-title":"Urology"},{"key":"10.1016\/j.jsbmb.2004.10.005_bib61","first-page":"370","article-title":"Neoadjuvant androgen deprivation prior to transperineal prostate brachytherapy: smaller volumes, less morbidity","volume":"5","author":"Blank","year":"1999","journal-title":"Cancer J. Sci. Am."},{"key":"10.1016\/j.jsbmb.2004.10.005_bib62","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.1016\/S0022-5347(05)65001-X","article-title":"Prostate volume reduction with antiandrogen deprivation therapy before interstitial brachytherapy","volume":"167","author":"Kucway","year":"2002","journal-title":"J. Urol."},{"key":"10.1016\/j.jsbmb.2004.10.005_bib63","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1056\/NEJM199707313370502","article-title":"Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin","volume":"337","author":"Bolla","year":"1997","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jsbmb.2004.10.005_bib64","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1016\/S0360-3016(00)01516-9","article-title":"Updated results of the phase III Radiation Therapy Oncology Group (RTOG) trial 85-31 evaluating the potential benefit of androgen suppression following standard radiation therapy for unfavorable prognosis carcinoma of the prostate","volume":"49","author":"Lawton","year":"2001","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"10.1016\/j.jsbmb.2004.10.005_bib65","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1016\/S0360-3016(01)01579-6","article-title":"Phase III Radiation Therapy Oncology Group (RTOG) trial 86-10 of androgen deprivation adjuvant to definitive radiotherapy in locally advanced carcinoma of the prostate","volume":"50","author":"Pilepich","year":"2001","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"10.1016\/j.jsbmb.2004.10.005_bib66","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1007\/s11934-003-0070-7","article-title":"Radiotherapy for T3 prostate cancer","volume":"4","author":"Bayley","year":"2003","journal-title":"Curr. Urol. Report"},{"key":"10.1016\/j.jsbmb.2004.10.005_bib67","first-page":"508","article-title":"A structured debate: immediate versus deferred androgen suppression in prostate cancer \u2013 evidence for deferred treatment","author":"Walsh","year":"2001","journal-title":"J. Urol."},{"key":"10.1016\/j.jsbmb.2004.10.005_bib68","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1046\/j.1464-410X.1997.d01-6840.x","article-title":"Immediate versus deferred treatment for advanced prostatic cancer: initial results of the Medical Research Council trial","volume":"79","year":"1997","journal-title":"Br. J. Urol."},{"key":"10.1016\/j.jsbmb.2004.10.005_bib69","doi-asserted-by":"crossref","first-page":"2030","DOI":"10.1016\/S0022-5347(01)63235-X","article-title":"Combined orchiectomy and external radiotherapy versus radiotherapy alone for nonmetastatic prostate cancer with or without pelvic lymph node involvement: a prospective randomised study","volume":"159","author":"Granfors","year":"1998","journal-title":"J. Urol."},{"key":"10.1016\/j.jsbmb.2004.10.005_bib70","doi-asserted-by":"crossref","first-page":"1992","DOI":"10.1016\/S0022-5347(05)66935-2","article-title":"Androgen receptor gene amplification at primary progression predicts response to combined androgen blockade as second line therapy for advanced prostate cancer","volume":"164","author":"Palmberg","year":"2000","journal-title":"J. Urol."},{"key":"10.1016\/j.jsbmb.2004.10.005_bib71","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/S0090-4295(01)01010-X","article-title":"Phase II trial of bicalutamide in patients with advanced prostate cancer in whom conventional hormonal therapy failed: a Southwest Oncology Group study (SWOG 9235)","volume":"58","author":"Kucuk","year":"2001","journal-title":"Urology"},{"key":"10.1016\/j.jsbmb.2004.10.005_bib72","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1038\/ng0495-401","article-title":"In vivo amplification of the androgen receptor gene and progression of human prostate cancer","volume":"9","author":"Visakorpi","year":"1995","journal-title":"Nat. Genet."},{"key":"10.1016\/j.jsbmb.2004.10.005_bib73","first-page":"314","author":"Koivisto","year":"1997","journal-title":"Cancer Res."},{"key":"10.1016\/j.jsbmb.2004.10.005_bib74","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1200\/JCO.1997.15.1.382","article-title":"Second-line hormonal therapy for advanced prostate cancer: a shifting paradigm (review)","volume":"15","author":"Small","year":"1997","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.jsbmb.2004.10.005_bib75","doi-asserted-by":"crossref","first-page":"1566","DOI":"10.1200\/JCO.1993.11.8.1566","article-title":"Flutamide withdrawal syndrome: its impact on clinical trial in hormone-refractory prostate cancer","volume":"11","author":"Scher","year":"1993","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.jsbmb.2004.10.005_bib76","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1038\/sj.bjc.6690024","article-title":"Controversies in the management of advanced prostate cancer","volume":"79","author":"Tyrrell","year":"1999","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.jsbmb.2004.10.005_bib77","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1016\/0090-4295(94)90092-2","article-title":"Prostate-specific antigen decline after casodex withdrawal: evidence for antiandrogen withdrawal syndrome","volume":"4","author":"Small","year":"1994","journal-title":"Urology"}],"container-title":["The Journal of Steroid Biochemistry and Molecular Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960076004003693?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960076004003693?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T20:47:52Z","timestamp":1760734072000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0960076004003693"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,11]]},"references-count":77,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2004,11]]}},"alternative-id":["S0960076004003693"],"URL":"https:\/\/doi.org\/10.1016\/j.jsbmb.2004.10.005","relation":{},"ISSN":["0960-0760"],"issn-type":[{"value":"0960-0760","type":"print"}],"subject":[],"published":{"date-parts":[[2004,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Endocrine treatment of prostate cancer","name":"articletitle","label":"Article Title"},{"value":"The Journal of Steroid Biochemistry and Molecular Biology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jsbmb.2004.10.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2004 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}